Drug Discovery in Africa ePanel with live Q&A

5 June 2019
Virtual event

Register to participate

Drug discovery research in Africa has lagged that carried out in the more developed nations of the world. Africa is often described as the “next frontier” in the global economy, yet a crippling disease burden continues to choke economic growth on the continent. It is thus vital for Africans to contribute to finding solutions to their health problems, which are not just African health problems but human health problems. Historically Africa has benefited immensely from medicines discovered and developed elsewhere. It is time for Africa to reciprocate and in the process contribute to the creation of science jobs in Africa as well as confront afro-pessimism and debunk the myth that Africa is not, and cannot be, a source of health innovation. However, many diseases endemic to Africa differ from those of more advanced economies or are often more severe.

The drive to find treatments and cures will be greatest where the impact will be highest - i.e., on the African continent. The lead for doing so has come from African academic institutions, and it is important to understand the types of partnerships and collaborations in Africa that can be made between academia, philanthropic organizations, governments and the pharmaceutical industry to optimize practices and minimize redundancies to deliver valuable new drugs. The lessons learned from doing successful drug discovery in an academic institution in Africa are also relevant to similarly inclined academic institutions worldwide, including those in more advanced economies.

Key areas that will be discussed during the ePanel are:

  • Why is it important to set up drug discovery operations in Africa?
  • The impediments to carrying out drug discovery in Africa, and the infrastructure/capacity/ capabilities that need to be developed.
  • The value proposition in Africa for drug discovery that may not be as accessible elsewhere.
  • The distinguishing features between pharmaceutical drug discovery and academic drug discovery, including those involving academic research institutes.
  • The translational work needed to channel fundamental academic research into productive drug discovery programs.
  • The operational models for academic research institutes and the challenges associated with them.
  • The role and operations of Product Development Partnerships (PDPs).
  • The paradigm shift for big pharma, academia and PDPs towards collaborative drug discovery.
  • What might be done to encourage and expand investment and engage the broader African community in drug discovery research.

Following the ePanel discussion broadcast, audience members watching the live event will be able to participate in a live Q&A with the panelists. Questions can be submitted during the broadcast via Twitter or the chat room, or in advance when registering for the event.

James Duffy

MMV's James Duffy is a member of the panel